Zura Bio (NASDAQ:ZURA) Given Neutral Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Zura Bio (NASDAQ:ZURA) in a report issued on Monday, Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock.

Other analysts have also recently issued research reports about the stock. Piper Sandler reaffirmed an “overweight” rating and set a $26.00 price objective on shares of Zura Bio in a research note on Thursday, September 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research note on Friday.

Zura Bio Stock Down 1.8 %

Shares of Zura Bio stock opened at $4.83 on Monday. Zura Bio has a twelve month low of $2.00 and a twelve month high of $6.35. The firm’s 50-day moving average price is $3.92 and its 200 day moving average price is $3.96.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). As a group, analysts anticipate that Zura Bio will post -0.47 earnings per share for the current year.

Insider Activity

In related news, Director Someit Sidhu sold 51,728 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now directly owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 15.80% of the company’s stock.

Hedge Funds Weigh In On Zura Bio

A number of hedge funds have recently modified their holdings of ZURA. AQR Capital Management LLC acquired a new position in shares of Zura Bio in the 2nd quarter worth approximately $43,000. Renaissance Technologies LLC raised its position in Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after purchasing an additional 5,900 shares during the period. SG Americas Securities LLC acquired a new position in Zura Bio during the third quarter worth $62,000. Forefront Analytics LLC boosted its position in shares of Zura Bio by 22.1% during the second quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock worth $145,000 after buying an additional 7,531 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after acquiring an additional 6,412 shares in the last quarter. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.